Evidence map›Paper›PMID 39072451›Full record

ArticleFuture medicinal chemistry2024

The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.

Leandro Dobrachinski, Leonardo Lg Ferreira, Maria E Cirino, Allan I Andrade-de-Siqueira, Ana C Mafud, Yvonne P Mascarenhas, Adriano D Andricopulo, Josué de Moraes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leandro DobrachinskiNúcleo de Pesquisa em Doenças Negligenciadas, Universidade Guarulhos, Guarulhos, SP, Brazil.
Leonardo Lg FerreiraInstituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil.ORCID 0000-0002-6947-0639
Maria E CirinoNúcleo de Pesquisa em Doenças Negligenciadas, Universidade Guarulhos, Guarulhos, SP, Brazil.
Allan I Andrade-de-SiqueiraNúcleo de Pesquisa em Doenças Negligenciadas, Universidade Guarulhos, Guarulhos, SP, Brazil.ORCID 0009-0000-9553-9647
Ana C MafudInstituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil.ORCID 0000-0002-9679-6079
Yvonne P MascarenhasInstituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil.ORCID 0000-0003-1918-114X
Adriano D AndricopuloInstituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP, Brazil.ORCID 0000-0002-0457-818X
Josué de MoraesNúcleo de Pesquisa em Doenças Negligenciadas, Universidade Guarulhos, Guarulhos, SP, Brazil.ORCID 0000-0003-1766-7031

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 13/07600-3
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Schistosoma mansoniUnited States Food and Drug AdministrationAnimalsDrug ApprovalHumansMiceModels, MolecularPharmacophoreSchistosomiasis mansoniSchistosomicidesUnited StatesSchistosomicidesAntiparasitic compoundsbetamethasonecomputational chemistry and molecular modellingdrug repositioninghelminthiasismedicinal chemistrypraziquantelschistosomiasisschistosomicidalvirtual screening

Identifiers

PMID39072451
PMCPMC11457623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.